Journal of Cardiac Failure
Volume 9, Issue 1 , Pages 4-12 , February 2003

The effect of digoxin on the quality of life in patients with heart failure

Received 14 May 2001 ,Revised 11 November 2002

References 

  1. American Heart Association . 2001 heart and stroke statistical update. Dallas, TX: American Heart Association,; 2000;
  2. Dracup K, Walden JA, Stevenson LW, Brecht M-L. Quality of life in patients with advanced heart failure. J Heart Lung Transplant. 1992;11:273–279
  3. Hawthorne MH, Hixon ME. Functional status, mood disturbance and quality of life in patients with heart failure. Prog Cardiovasc Nursing. 1994;9(1):22–32
  4. Rogers WJ, Johnstone DE, Yusuf S, Weiner DH, Gallagher P, Bittner VA, et al.  Quality of life among 5025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1994;23:393–400
  5. The CONSENSUS trial study group . Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–1435
  6. Gundersen T, Wiklund I, Swedberg K, Amtorp O, Remes J, Nilsson B. Effects of 12 weeks of ramipril treatment on the quality of life in patients with moderate congestive heart failure: results of a placebo-controlled trial. Cardiovasc Drugs Ther. 1995;9:589–594
  7. MERIT-HF Study Group . Effects of controlled-release Metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure. JAMA. 2000;283:1295–1302
  8. The Digitalis Investigation Group . The effect of digoxin on mortality and morbidity in patients with congestive heart failure. N Engl J Med. 1997;336:525–533
  9. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol. 1993;22:955–962
  10. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, et al.  Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med. 1993;329:1–7
  11. The Digitalis Investigation Group . Rationale, design, implementation, and baseline characteristics of patients in the DIG Trial: A large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. Cont Clin Trials. 1996;17:77–97
  12. Guyatt GH, Thompson PJ, Berman LB, Sullivan MJ, Townsend M, Jones SL, et al.  How should we measure function in patients with chronic heart and lung disease?. J Chronic Dis. 1985;38:517–524
  13. Ware JE, Sherbourne CD. The MOS 36-item Short Form Health Survey (SF-36): 1. Conceptual framework and item selection. Med Care. 1992;30:473–483
  14. Cantril H. The pattern of human concern. New Brunswick, NJ: Rutgers University; 1995;
  15. Radloff LF. The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Measurement. 1977;1:385–401
  16. Spielberger CD, Gorsuch RL, Lushene RE. Manual for the State-Trait Anxiety Inventory. Paolo Alto, CA: Consulting Psychologists Press; 1970;
  17. Spielberger CD, Jacobs G, Russell S, Crane R. Assessment of anger: The State-Trait Anger Scale. In:  Butcher JN,  Spielberger CD editor. Advances in personality assessment. Hillsdale, NJ: Lawrence Erlbaum; 1983;
  18. Rector TS, Kubo SH, Cohn JN. Patients' self-assessment of their congestive heart failure. Part 2: Content, reliability and validity of a new measure: The Minnesota Living With Heart Failure Questionnaire. Heart Fail October/November. 1987;198–209
  19. Garg R, Czajkowski S, Hunsberger S, Horney A. Assessment of health-related quality of life and six-minute walk tests in the DIG Study. In: Second Annual Symposium of Contributed Papers on Quality of Life Evaluation (DIA Meeting), Charleston, SC. October 1994;
  20. Hollander M, Wolfe DA. Nonparametric statistical methods. New York: John Wiley & Sons; 1973;
  21. Miller RG. Simultaneous statistical inference. 2nd ed. New York: Springer Verlag; 1981;
  22. Lehmann EL. Nonparametrics: Statistical methods based on ranks. Oakland, CA: Holden-Day; 1975;
  23. Institute Inc SAS. SAS language: Reference, version 6. Cary, NC: SAS Institute, Inc; 1990;
  24. Little RJA, Rubin DB. Statistical analysis with missing data. New York: John Wiley & Sons; 1987;
  25. Wiklund I, Waagstein F, Swedberg K, Hjalmarsson A. Quality of life on treatment with metoprolol in dilated cardiomyopathy: Results from the MDC trial. Cardiovasc Drugs Ther. 1996;10:361–368
  26. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA investigators. Circulation. 1996;94:2807–2816
  27. Cohn JN, Archibald DG, Ziesche S. Effect of vasodilator therapy on mortality in congestive heart failure: Results of the Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547–1552
  28. Rector TS, Johnson G, Dunkman WB, for the V-HeFT VA, Cooperative Studies Group . Evaluation of patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. Circulation. 1993;87(suppl VI):71–77
  29. Blackwood R, Mayou RA, Garnham JC, Armstrong C, Bryant B. Exercise capacity and quality of life in the treatment of heart failure. Clin Pharmacol Ther. 1990;48:325–332
  30. Braunholtz DA, Edwards SJ, Lilford RJ. Are random-ized clinical trials good for us (in the short term)? Evidence for a “trial effect.”. J Clin Epidemiol. 2001;54:217–224
  31. Cowley AJ, Skene AM. Treatment of severe heart failure: quantity or quality of life? Trial of enoximone. Enoximone Investigators. Br Heart J. 1994;72:226–230
  32. Lee C, Johnson RA, Bingham GB, et al.  Heart failure in outpatients. N Engl J Med. 1982;306:699–705
  33. Captopril-digoxin multicenter research group . Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA. 1988;259:539–544
  34. Gheorghiade M, St. Clair J, Beller GA. Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. JACC. 1987;9:849–857
  35. Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG. Sympathoinhibitory responses to digitalis glycosides in heart failure: Direct evidence from sympathetic neural recordings. Circulation. 1989;80:65–77
  36. Wang W, Chen JW, Zucker I. Carotid sinus baroreceptor sensitivity in experimental heart failure. Circulation. 1990;81:1959–1966
  37. Franciosa JA, Park M, Levine TB. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am J Cardiol. 1981;47:33–39
  38. Young JB, Gheorghiade M, Packer M, Uretsky B, Hull H, on behalf of the PROVED and RADIANCE investigators . Are low serum levels of digoxin effective in chronic heart failure?. J Am Coll Cardiol. 1993;21:378A

☆ The study was conducted by the National Heart, Lung, and Blood Institute of the National Institutes of Health, and the Department of Veterans Affairs Cooperative Studies program; Glaxo Wellcome supplied digoxin and placebo.

☆☆ Reprint requests: Cooperative Studies Program Coordinating Center, Research–151 E, PO Box 1010, Perry Point, MD 21902-1010.

PII: S1071-9164(02)25407-X

doi: 10.1054/jcaf.2003.7

Journal of Cardiac Failure
Volume 9, Issue 1 , Pages 4-12 , February 2003

Article Tools